Stemline Therapeutics (STML) PT Lowered to $10 at Cantor Fitzgerald
Tweet
Share
E-mailGet Alerts STML Hot Sheet
Price: $11.83 --0%
Rating Summary:
6 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 11 | New: 13
Rating Summary:
6 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 11 | New: 13
Join SI Premium – FREE
Cantor Fitzgerald analyst Alethia Young lowered the price target on Stemline Therapeutics (NASDAQ: STML) to $10.00 (from $18.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Fiserv (FI) PT Raised to $175 at TD Cowen
- Quest Diagnostics (DGX) PT Raised to $145 at Evercore ISI
- South32 Limited (S32:AU) (SHTLF) PT Lowered to AUD4 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
